BR112013025481B8 - Composições farmacêuticas, uso destas e kits para prevenir e/ou tratar uma doença por hiv em humanos - Google Patents

Composições farmacêuticas, uso destas e kits para prevenir e/ou tratar uma doença por hiv em humanos

Info

Publication number
BR112013025481B8
BR112013025481B8 BR112013025481A BR112013025481A BR112013025481B8 BR 112013025481 B8 BR112013025481 B8 BR 112013025481B8 BR 112013025481 A BR112013025481 A BR 112013025481A BR 112013025481 A BR112013025481 A BR 112013025481A BR 112013025481 B8 BR112013025481 B8 BR 112013025481B8
Authority
BR
Brazil
Prior art keywords
humans
treat
pharmaceutical compositions
kits
preventing
Prior art date
Application number
BR112013025481A
Other languages
English (en)
Other versions
BR112013025481A2 (pt
BR112013025481B1 (pt
Inventor
Andrieu Jean-Marie
Lu Louis
Original Assignee
Univ Paris Descartes
Biovaxim Ltd
Institute De Rech Pour Le Developpement I R D
Univ Paris
Univ Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46969619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013025481(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Paris Descartes, Biovaxim Ltd, Institute De Rech Pour Le Developpement I R D, Univ Paris, Univ Paris Cite filed Critical Univ Paris Descartes
Publication of BR112013025481A2 publication Critical patent/BR112013025481A2/pt
Publication of BR112013025481B1 publication Critical patent/BR112013025481B1/pt
Publication of BR112013025481B8 publication Critical patent/BR112013025481B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

COMPOSIÇÕES FARMACÊUTICAS PARA PREVENIR E/OU TRATAR UMA DOENÇA POR HIV EM HUMANOS. A presente invenção refere-se a composições farmacêuticas compreendendo uma mistura de um antígeno do HIV específico e uma bactéria viva não patogênica. O referido antígeno de HIV específico compreende um ou mais epítopos provenientes de proteínas Gag e/ou Pol e está preferivelmente sob a forma de particulado. A referida bactéria é preferivelmente Lactobacillus plantarum. Estas composições são utilizáveis para prevenir e/ou tratar doença provocada por HIV em humanos.
BR112013025481A 2011-04-06 2012-04-06 Composições farmacêuticas, uso destas e kits para prevenir e/ou tratar uma doença por hiv em humanos BR112013025481B8 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CNPCT/CN2011/072481 2011-04-06
CNPCT/CN2011/072481 2011-04-06
US201161534088P 2011-09-13 2011-09-13
US61/534,088 2011-09-13
CNPCT/CN2012/070761 2012-01-30
CNPCT/CN2012/070761 2012-01-30
US201261609051P 2012-03-09 2012-03-09
US61/609,051 2012-03-09
PCT/IB2012/000857 WO2012137071A2 (en) 2011-04-06 2012-04-06 Pharmaceutical compositions for preventing and/or treating an hiv disease in humans

Publications (3)

Publication Number Publication Date
BR112013025481A2 BR112013025481A2 (pt) 2018-12-11
BR112013025481B1 BR112013025481B1 (pt) 2020-06-23
BR112013025481B8 true BR112013025481B8 (pt) 2022-11-22

Family

ID=46969619

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025481A BR112013025481B8 (pt) 2011-04-06 2012-04-06 Composições farmacêuticas, uso destas e kits para prevenir e/ou tratar uma doença por hiv em humanos

Country Status (19)

Country Link
US (1) US9839684B2 (pt)
EP (3) EP3173096A1 (pt)
JP (1) JP6054370B2 (pt)
KR (1) KR101814857B1 (pt)
CN (1) CN105709221B (pt)
AP (1) AP2013007166A0 (pt)
AU (1) AU2012238351B2 (pt)
BR (1) BR112013025481B8 (pt)
CA (1) CA2832022C (pt)
CL (1) CL2013002836A1 (pt)
DK (1) DK2694101T3 (pt)
ES (1) ES2606511T3 (pt)
IL (1) IL228666A (pt)
MX (1) MX343037B (pt)
PL (1) PL2694101T3 (pt)
PT (1) PT2694101T (pt)
RU (1) RU2609769C2 (pt)
SG (1) SG194079A1 (pt)
WO (1) WO2012137071A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1397155E (pt) * 2001-06-21 2015-12-07 Genentech Inc Formulação de libertação sustentada
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
CN107249627B (zh) * 2015-01-30 2021-06-29 国立大学法人东京大学 含有来自hpv e7蛋白质的多肽的乳酸菌的组合物
US11077185B2 (en) 2019-03-21 2021-08-03 21C Bio Vaccine to pathogenic immune activation cells during infections
AU2020243095A1 (en) * 2019-03-21 2021-10-21 21C Bio Vaccine to pathogenic immune activation cells during infections
CN115996737A (zh) * 2020-01-10 2023-04-21 依米诺比姆有限公司 新型植物乳杆菌菌株、源自菌株的多糖及其用途
CN117202926A (zh) * 2021-02-02 2023-12-08 普罗瓦克萨斯股份有限公司 新型免疫调节平台及其使用方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243029A1 (en) 1986-04-08 1987-10-28 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Recombinant vaccinia virus expressing human retrovirus gene
JPS6485072A (en) 1987-09-25 1989-03-30 Nat Inst Health Recombinant vaccinia virus
JPH01148183A (ja) 1987-12-04 1989-06-09 Hiroshi Shibuta 組み換えワクチニアウイルス
JP3140757B2 (ja) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5861282A (en) 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
JPH05503629A (ja) 1989-11-20 1993-06-17 オンコーゲン　リミテッド　パートナーシップ 抗ウィルス剤及び免疫原として使用される、非複製組換え製レトロウィルス粒子
DE69131513T3 (de) 1990-03-21 2005-05-25 Geneart Gmbh Für abgeänderte retrovirale GAG-Polypeptide kodierende DNA-Sequenzen und diese enthaltende Impfstoffe oder Aggregate davon
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
CA2110489A1 (en) 1991-06-14 1992-12-23 Enzo Paoletti Immunodeficiency virus recombinant poxvirus vaccine
DK0538496T3 (da) 1991-08-26 2004-02-23 Baxter Healthcare Sa Rekombinant fjerkrækoppevirus med intakt FPV tk-gen
DE4141741A1 (de) 1991-12-13 1993-06-17 Gisela Kielmann Verfahren zur bekaempfung des human imune deficiency virus
US6511845B1 (en) 1992-08-07 2003-01-28 Alan R. Davis Methods for producing an immune response against HIV-1
US6136318A (en) 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
WO1995007099A1 (fr) 1993-09-09 1995-03-16 The Nisshin Oil Mills, Ltd. Vaccin et procede pour sa production
JPH07170982A (ja) 1993-09-09 1995-07-11 Nisshin Oil Mills Ltd:The ワクチンおよびその製造方法
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
AU3958895A (en) 1994-10-18 1996-05-06 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
JPH11507241A (ja) 1995-06-07 1999-06-29 シントロ・コーポレーション 組換え鶏痘ウイルスおよびその使用
US5741492A (en) 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
JPH1085072A (ja) 1996-09-13 1998-04-07 Kichinosuke Takemaru 家具転倒防止器具
US6001155A (en) 1997-03-17 1999-12-14 Pease; John R. Polyphasic pressurized homogenizer
HRP980143A2 (en) * 1997-04-09 1999-02-28 Soo Sung Ko 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
US5895758A (en) * 1997-06-10 1999-04-20 Bio-Energy Systems Strain of lactobacillus Plantarum
CA2293826A1 (en) 1997-06-11 1998-12-17 Brigitte Gicquel Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
JP3899165B2 (ja) 1997-08-06 2007-03-28 ビー・エル・オートテック株式会社 ロボットアームの過負荷保護装置
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6121021A (en) 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
US7189402B1 (en) 1998-02-06 2007-03-13 Research Development Foundation Live vaccine for human immunodeficiency virus
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
US20040009936A1 (en) 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
WO2001002607A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
EP1084709A1 (en) 1999-09-17 2001-03-21 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Oral recombinant lactobacilli vaccines
JP2003512077A (ja) 1999-10-26 2003-04-02 インターナショナル エイズ バクシーン イニシアティブ アルファウイルスレプリコンを発現する侵襲性細菌
US20040105871A1 (en) 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US20020155127A1 (en) 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU2001294562B2 (en) 2000-09-15 2007-05-24 Merck & Co., Inc. Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications
US20040101957A1 (en) 2001-09-14 2004-05-27 Emini Emilio A. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
WO2002031168A2 (en) 2000-10-10 2002-04-18 Genstar Therapeutics Minimal adenoviral vector and recombinant vaccines based thereon
GB0030857D0 (en) 2000-12-18 2001-01-31 Medical Res Council Therapeutic compositions
KR20020059856A (ko) 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
JP4554887B2 (ja) 2001-03-08 2010-09-29 アメリカ合衆国 改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ
WO2002102409A1 (en) 2001-06-19 2002-12-27 Medical Research Council Inactivated mycobacterial ompatb and uses thereof
US20040253210A1 (en) 2001-08-30 2004-12-16 Marjorie Robert-Guroff Adenovirus type7 vectors
US20070077257A1 (en) 2001-09-14 2007-04-05 Emini Emilio A Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications
WO2003051288A2 (en) 2001-11-14 2003-06-26 Novavax, Inc. Mycobacterial vaccine
AU2002360353A1 (en) 2001-12-11 2003-06-23 University Of Iowa Research Foundation Receptor-targeted adenoviral vectors
US20040009937A1 (en) 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
WO2003063786A2 (en) 2002-01-31 2003-08-07 Symbigene, Inc. Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
ATE424464T1 (de) 2002-04-26 2009-03-15 Inst Nat Sante Rech Med Verbesserte chimäre glykoproteine und pseudotypisierte lentivirale vektoren
JP2003321391A (ja) 2002-04-30 2003-11-11 Japan Science & Technology Corp 組換えワクシニアウイルスを用いたｈｉｖワクチン
DE10221411B4 (de) 2002-05-14 2004-07-08 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Rekombinantes Fowlpox-Virus
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
WO2003101394A2 (en) * 2002-05-31 2003-12-11 Ciphergen Biosystems, Inc. Defensins: use as antiviral agents
CN1490056A (zh) 2002-10-18 2004-04-21 ��¡���ɵ°��̲��о����� 针对hiv-1的免疫方法和组合物
EP2371380A1 (en) 2003-03-28 2011-10-05 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
JP2007518460A (ja) 2003-05-09 2007-07-12 イントラヴァック インコーポレーテッド 皮内、皮下及び筋肉内注射用の無針注射器及びアンプル
US20100189747A1 (en) 2003-07-31 2010-07-29 Raymond Weinstein Compositions and methods for treating or preventing hiv infection
CA2535527A1 (en) * 2003-08-28 2005-03-10 The Immune Response Corporation Immunogenic hiv compositions and related methods
JP2007037402A (ja) 2003-11-28 2007-02-15 Primmune:Kk 抗ヒト免疫不全ウイルス感染防御用キメラ５型／３５型アデノウイルスベクター
WO2005111205A1 (en) 2004-05-18 2005-11-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
WO2005121378A2 (en) * 2004-06-03 2005-12-22 Saint Louis University Methods and compositions for vaccination
WO2006012320A1 (en) 2004-06-25 2006-02-02 Dow Agrosciences Llc Process for the preparation of 4-trifluoromethyl-2(1h)-pyridinone
WO2006026667A2 (en) 2004-08-27 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes
RU2396346C2 (ru) * 2004-10-04 2010-08-10 Биоваксим Лимитед Применение инактивированного цельного вируса совместимого субтипа для получения бесклеточной вакцины и способ лечения вич-инфекции
CA2853335A1 (en) * 2005-02-24 2006-11-23 Medical Research Council Hivcon: an hiv immunogen and uses thereof
JP5175178B2 (ja) 2005-05-12 2013-04-03 グラクソ グループ リミテッド ワクチン組成物
EP1723965A1 (en) 2005-05-18 2006-11-22 Stallergenes Sa Compositions for antigen-specific induction of immuno-tolerance via oral immunization
US20100028449A1 (en) 2006-06-06 2010-02-04 Satya Prakash Fermented milk product and use thereof
SI2144626T1 (sl) 2007-04-12 2015-04-30 Mico Bio, Inc. Cepivo proti tuberkulozi in postopek za njegovo uporabo
WO2009093900A1 (en) 2008-01-25 2009-07-30 Stichting Top Institute Food And Nutrition Mid-log phase lactic acid bacteria for inducing immune tolerance in a subject

Also Published As

Publication number Publication date
EP3173096A1 (en) 2017-05-31
MX2013011540A (es) 2014-04-16
CN105709221A (zh) 2016-06-29
WO2012137071A2 (en) 2012-10-11
ES2606511T3 (es) 2017-03-24
KR20140042800A (ko) 2014-04-07
US9839684B2 (en) 2017-12-12
AU2012238351A1 (en) 2013-10-24
EP2694101B1 (en) 2016-09-14
KR101814857B1 (ko) 2018-01-04
IL228666A (en) 2017-12-31
JP6054370B2 (ja) 2016-12-27
NZ616283A (en) 2014-10-31
EP3000476A1 (en) 2016-03-30
RU2013147745A (ru) 2015-05-20
RU2609769C2 (ru) 2017-02-02
CN105709221B (zh) 2020-11-17
IL228666A0 (en) 2013-12-31
WO2012137071A3 (en) 2012-11-29
US20140302089A1 (en) 2014-10-09
BR112013025481A2 (pt) 2018-12-11
MX343037B (es) 2016-10-20
PL2694101T3 (pl) 2017-07-31
EP2694101A2 (en) 2014-02-12
SG194079A1 (en) 2013-11-29
JP2014511856A (ja) 2014-05-19
CA2832022C (en) 2019-01-08
AU2012238351B2 (en) 2016-11-24
AP2013007166A0 (en) 2013-10-31
DK2694101T3 (en) 2017-01-09
PT2694101T (pt) 2016-12-19
CA2832022A1 (en) 2012-11-10
CL2013002836A1 (es) 2014-07-25
BR112013025481B1 (pt) 2020-06-23

Similar Documents

Publication Publication Date Title
BR112013025481B8 (pt) Composições farmacêuticas, uso destas e kits para prevenir e/ou tratar uma doença por hiv em humanos
BR112019000338A2 (pt) composições compreendendo cepas bacterianas
BR112018077266A2 (pt) composições compreendendo cepas bacterianas
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
UA112416C2 (uk) Антитіло до fap і способи його застосування
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
CY1123056T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
CO6650338A2 (es) Antígenos de tuberculosis modificados
BR112013003722A2 (pt) produtos para cuidado e métodos de uso e fabricação dos mesmos
EA201170295A1 (ru) ИНГИБИТОРЫ сМЕТ
BR112012022755A2 (pt) composição com bactérias probióticas para uso no tratamento de distúrbios imunológicos
BR112016000072A2 (pt) composições orais
BR112014005810A2 (pt) formas sólidas de um inibidor da dissociação de transtirretina
PH12015501361A1 (en) Method for activating helper t cell
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
BR112016023754A2 (pt) ?uso de lactobacillus paracasei para promover recuperação da diversidade da microbiota intestinal após disbiose?
CY1120468T1 (el) Εξανθρωπισμενα αντισωματα il-25
EA201400447A1 (ru) АНТИТЕЛА К CD1d
BR112016023752A2 (pt) utilização de lactobacillus rhamnosus para promover a recuperação da diversidade da microbiota intestinal após disbiose
BR112017010832A2 (pt) composições de aminoácido para o tratamento de sintomas de doença

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/04/2012, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: BIOVAXIM LIMITED (GB) ; INSTITUTE DE RECHERCHE POUR LE DEVELOPPEMENT (I.R.D) (FR) ; UNIVERSITE DE PARIS (FR)

B25D Requested change of name of applicant approved

Owner name: BIOVAXIM LIMITED (GB) ; INSTITUTE DE RECHERCHE POUR LE DEVELOPPEMENT (I.R.D) (FR) ; UNIVERSITE PARIS CITE (FR)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2717 DE 31-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.